Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: A multiinstitutional validation study

Cancer

Volumn 97, Issue 4, 2003, Pages 969-978

  Haese, Alexander ^a   Chaudhari, Manisha ^a   Miller, M Craig ^b   Epstein, Jonathan I ^a   Huland, Hartwig ^c   Palisaar, Juri ^c   Graefen, Markus ^c   Hammerer, Peter ^c   Poole, Edward C ^d   O'Dowd, Gerard J ^d   Partin, Alan W ^a   Veltri, Robert W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Immunicon Corporation   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UroCor Incorporated   (United States)

Author keywords

Artificial neural network; Iogistic regression; Prostate carcinoma staging; Quantitative biopsy pathology; UroScore

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; TREATMENT PLANNING; VALIDATION PROCESS;

BIOPSY; CARCINOMA; COMPUTATIONAL BIOLOGY; HUMANS; LYMPH NODE EXCISION; MALE; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 0037441907     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11153     Document Type: Article

References (29)

1. Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000;164:1591-1595.
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-848.
3. Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology. 1995;46:205-212.
4. Graefen M, Haese A, Pichlmeier U, et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol. 2001;165:857-863.
5. Veltri RW, Miller MC, Partin AW, Poole EC, O'Dowd GJ. Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer. 2001;91:2322-2328.
6. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997;79: 528-537.
7. Vollmer RT, Keetch DW, Humphrey PA. Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. Cancer. 1998;83:1567-1580.
8. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
9. D'Amico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000;55:572-577.
10. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001;166:1322-1327.
11. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562-1568.
12. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996;77:2162-2166.
13. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
14. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in clinical Stage Tlc prostate cancer patients: the new challenge. J Urol. 2002;168:100-104.
15. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 1998;51:186-195.
16. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol. 1997;158(3 Pt 1):687-698.
17. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology. 1998;51:759-764.
18. Badalament RA, Miller MC, Peller PA, et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol. 1996;156:1375-1380.
19. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163:174-178.
20. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol. 1998;16:106-117.
21. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;3:555-565.
22. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeat biopsy results within one year following a non-cancer diagnosis. Urology. 2000;55:553-559.
23. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
24. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology. 1997;8:126-131.
25. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology. 1997;11:180-193.
26. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
27. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol. 2000;38:74-78.
28. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286-292.
29. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231-1234.